Proper use of serum antibody titres against Epstein-Barr virus in nasopharyngeal carcinoma: IgA/virus capsid antigen for diagnosis and EBV- related nuclear antigen-2 for follow-up

Acta Oto-Laryngologica

Volumn 120, Issue 1, 2000, Pages 100-104

  Shimakage, Misuzu ^a   Dezawa, Toru ^b   Chatani, Masashi ^c  

^a OSAKA NATIONAL HOSPITAL   (Japan)

^b Kinan General Hospital   (Japan)

^c OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

Differential screening methods; Family case; Human herpesvirus 4

Indexed keywords

CELL NUCLEUS ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN; IMMUNOGLOBULIN A ANTIBODY; VIRUS CAPSID ANTIGEN;

ADULT; AGE; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ANTIGEN DETECTION; ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER SCREENING; CARCINOGENESIS; CLINICAL ARTICLE; CORRELATION FUNCTION; EPSTEIN BARR VIRUS; FAMILY STUDY; FEMALE; FOLLOW UP; HERPES SIMPLEX VIRUS; HUMAN; IMMUNOFLUORESCENCE; IMMUNOPATHOLOGY; MALE; MALIGNANT TRANSFORMATION; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; TITRIMETRY;

EID: 0033932930     PISSN: 00016489     EISSN: None     Source Type: Journal    
DOI: 10.1080/00016480060203325     Document Type: Article

References (23)

1. 1. Epstein MA, Achong BG. Introductory considerations. In: Epstein MA, Achong BG, eds. The Epstein-Barr virus: recent advances. London: William Heineman Medical Books, 1986: 2-11.
2. 2. Zeng Y. Seroepidemiological studies on nasopharyngeal carcinoma in China. Adv Cancer Res 1985; 44: 121-38.
3. 3. Wolf H, zur Hauzen H, Becker V. EB viral genomes in epithelial nasopharyngeal carcinoma cells. Nature 1973; 244: 245-7.
4. 4. Raab-Traub N, Hood R, Yang CS, Henry B, Pagano JS. Epstein-Barr virus transcription in nasopharyngeal carcinoma. J Virol 1983; 48: 580-90.
5. 5. Young LS, Dawson CW, Clark D, Rupani H, Busson P, Tursz T, et al. Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol 1988; 69: 1051-65.
6. 6. Zheng X, Yan L, Nilsson B, Eklund G, Drettner B. Epstein-Barr virus infection, salted fish and nasopharyngeal carcinoma. A case-control study in Southern China. Acta Oncol 1994; 33: 867-72.
7. 7. Zheng XI, Christensson B, Drettner B. Studies on etiological factors of nasopharyngeal carcinoma. Acta Otolaryngol 1993; 113: 455-7.
8. 8. Sheen TS, Ko JY, Chang YL, Chang YS, Huang YT, Chang Y, et al. Nasopharyngeal swab and PCR for the screening of nasopharyngeal swab and PCR for the screening of nasopharyngeal carcinoma in the endemic area: a good supplement to the serologic screening. Head Neck 1998; 20: 732-8.
9. 9. Shimakage M, Ikegami N, Chatani M, Yoshino K, Sato T. Serological follow-up study on the antibody levels to Epstein-Barr virus-determined nuclear antigen (EBNA) in patients with nasopharyngeal carcinoma(NPC) after radiation therapy. Biken J 1987; 30: 45-51.
10. 10. Chatani M, Teshima T, Inoue T, et al. Antibody response against the Epstein-Barr virus-coded nuclear antigen 2 (EBNA2) in nasopharyngeal carcinoma. Laryngoscope 1991; 101: 626-9.
11. 11. UICC, TNM classification of malignant tumours. Geneva: UICC, 1979.
12. 12. IARC, Recommendations. In: G. de-The, Y. Ito, eds. Nasopharyngeal carcinoma: etiology and control. IARC, Lyon: IARC Scientific Publ. 1978; 20: 593-6.
13. 13. de-Vathaire F, Sancho-Garnier H, de-The H, et al. Prognostic value of EBV markers in the clinical management of nasopharyngeal carcinoma (NPC): a multi-center follow-up study. Int J Cancer 1988; 42: 176-81.
14. 14. Sam C-K, Abu-Samah AJ, Prasad U. IgA/VCA as a follow-up marker in the monitoring of nasopharyngeal carcinoma. Eur J Surg Oncol 1994; 20: 561-4.
15. 15. Deng H, Zeng Y, Lei Y, Zhao Z, et al. Serological survey of nasopharyngeal carcinoma in 21 cities of south China. Chin Med J 1995; 108: 300-3.
16. 16. Shimakage M, Sasagawa T, Yoshino K, et al. Expression of Epstein-Barr virus in mesopharyngeal and hypopharyngeal carcinomas. Hum Pathol 1999; 30: 1071-6.
17. 17. Frech B, Zimber-Strobl U, Yip TTC, Lau WH, Mueller-Lantzsch N. Characterization of the antibody response to the latent infection terminal proteins of Epstein-Barr virus in patients with nasopharyngeal carcinoma. J Gen Virol 1993; 74: 811-8.
18. 18. Liu MY, Shih YY, Chou SP, et al. Antibody against the Epstein-Barr virus BHRF1 protein, a homologue ofbcl-2, in patients with nasopharyngeal carcinoma. J Med Virol 1998; 56: 179-85.
19. 19. Shimakage M, Kurata A, Inoue H, Yutsudo M, Hakura A. Tumorigenicity of EBNA2-transfected cells. FEBS Lett 1995; 371: 245-8.
20. 20. Shimakage M, Miyata Y, Inoue H, Yutsudo M, Hakura A. Increased sensitivity of EBNA2-transfected rat fibroblasts to ionizing radiation. Int J Cancer 1996; 68: 612-5.
21. 21. Cochet C, Martel-Renoir D, Grunewald V, et al. Expression of the Epstein-Barr virus immediate early gene, BZLF1, in nasopharyngeal carcinoma tumor cells. Virology 1993; 197: 358-65.
22. 22. Martel-Renoir D, Grunewald V, Touitou R, Schwab G, Joab I. Qualitative analysis of expression of Epstein-Barr virus lytic genes in nasopharyngeal carcinoma biopsies. J Gen Virol 1995; 76: 1401-8.
23. 23. Snow JB Jr. Carcinoma of nasopharynx in children. Ann Otol 1975; 84: 817-26.